DNA - Latest News
Ginkgo Bioworks Holdings, Inc. (DNA), operates in Healthcare / Biotechnology, trades on NYSE.
Market capitalization stands near $669.6M. Beta to the broader market is 1.80.
The article list below shows the most recent DNA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent DNA Headlines
Palantir's Bold Biosecurity Opportunity Could Be Bigger Than Investors Think
fool.com - Jun 28, 2026
A new biosecurity theme is emerging, and Palantir is leveraging it as an opportunity. Here's why that divide could matter for investors.
FTAI Aviation: Innovation Is Their DNA
seekingalpha.com - Jun 7, 2026
FTAI Aviation is innovatively leveraging jet engine cores to address the urgent power needs of data centers amid an energy bottleneck. FTAI's new pow
Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
businesswire.com - Jun 1, 2026
BOULDER, Colo. --(BUSINESS WIRE)-- #ArcherAnalysis--IDT's library prep solutions join Illumina's extensive software ecosystem to enable streamlined an
Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio
businesswire.com - May 29, 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announc
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
prnewswire.com - May 26, 2026
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrat
How News Affects DNA Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track DNA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked DNA news questions
- What is the latest DNA news headline?
- The most recent DNA headline (Jun 28, 2026) is "Palantir's Bold Biosecurity Opportunity Could Be Bigger Than Investors Think". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the DNA news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What DNA news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual DNA options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.